A Study to See if we Can Predict How Your Liver Tumor or Liver Metastases Will Respond to Trans-Arterial Embolization (TAE)

Memorial Sloan Kettering Cancer Center (MSK)

Status: Withdrawn

Conditions: Liver Metastases; Liver Cancer

Treatments: Procedure: biopsy; Device: MRI/CT scan; Procedure: Hepatic trans-arterial embolization (TAE); Other: blood draw

Study type: Observational

Funder types: Other

Identifiers

NCT02772575

16-385

Details and patient eligibility

About

The purpose of this study is to see if certain genes the tumor can help predict how the tumor will respond to Trans-Arterial Embolization (TAE). A gene is the basic physical and functional unit of heredity. Genes are made up of DNA; DNA (deoxyribonucleic acid) is the hereditary material in humans. Identifying a gene that can predict how liver tumors will respond to TAE will also help to determine if adjuvant therapy will be needed after TAE.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histopathologic evidence of primary liver cancer or liver metastases
• Indication of TAE for the treatment of liver tumor
• Age ≥ 18 years
• Available tissue with adequate tissue for analysis, verified by a pathologist

Exclusion criteria

• History of a second active malignancy with evidence of metastatic disease

Trial design

0 participants in 1 patient group

patients with primary liver or liver metastases

Description:

A biopsy will be performed as standard of care either at time of Hepatic trans-arterial embolization (TAE) or within 4 months prior to TAE. TAE is a standard of care procedure. Within 8 weeks of TAE, patient will have a clinic visit which will include medical history, physical examination, vital signs, EKG (if one is not available), and ECOG assessment. Additionally a dedicated liver CT or MR will be obtained as well as standard of care labs. IMPACT blood test will be performed at the time of any of the standard of care labs. As IMPACT platform at MSKCC continually evolves to include more genes, we will use the platform available at the time of initiation of the protocol, therefore all patients will be subjected to the same platform. RNA-seq has been demonstrated to be superior in detecting low abundance transcripts, demonstrating a broader dynamic range, and detecting different isoforms and genetic variants.

Treatment:

Other: blood draw

Procedure: biopsy

Device: MRI/CT scan

Procedure: Hepatic trans-arterial embolization (TAE)